1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alimta
1.4.3 Iressa
1.4.4 Avastin
1.4.5 Tarceva
1.4.6 Zykadia
1.4.7 Tagrisso
1.4.8 Xalkori
1.4.9 Cyramza
1.4.10 Opdivo
1.5 Market by Application
1.5.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Non-small Cell Lung Cancer Therapeutics Market
1.8.1 Global Non-small Cell Lung Cancer Therapeutics Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Non-small Cell Lung Cancer Therapeutics Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Non-small Cell Lung Cancer Therapeutics Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Non-small Cell Lung Cancer Therapeutics Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Non-small Cell Lung Cancer Therapeutics Sales Volume Market Share by Region (2015-2020)
3.2 Global Non-small Cell Lung Cancer Therapeutics Sales Revenue Market Share by Region (2015-2020)
3.3 North America Non-small Cell Lung Cancer Therapeutics Sales Volume
3.3.1 North America Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.3.2 North America Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume
3.4.1 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.5.1 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.6.1 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.7.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.8.1 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.9.1 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.10.1 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.11.1 South America Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.11.2 South America Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume (2015-2020)
3.12.1 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Non-small Cell Lung Cancer Therapeutics Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Non-small Cell Lung Cancer Therapeutics Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Non-small Cell Lung Cancer Therapeutics Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Non-small Cell Lung Cancer Therapeutics Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Non-small Cell Lung Cancer Therapeutics Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Non-small Cell Lung Cancer Therapeutics Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Non-small Cell Lung Cancer Therapeutics Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Non-small Cell Lung Cancer Therapeutics Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Non-small Cell Lung Cancer Therapeutics Sales Volume Market Share by Type (2015-2020)
14.2 Global Non-small Cell Lung Cancer Therapeutics Sales Revenue Market Share by Type (2015-2020)
14.3 Global Non-small Cell Lung Cancer Therapeutics Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Non-small Cell Lung Cancer Therapeutics Consumption Volume by Application (2015-2020)
15.2 Global Non-small Cell Lung Cancer Therapeutics Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Non-small Cell Lung Cancer Therapeutics Business
16.1 GlaxoSmithKline
16.1.1 GlaxoSmithKline Company Profile
16.1.2 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Product Specification
16.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Sanofi
16.2.1 Sanofi Company Profile
16.2.2 Sanofi Non-small Cell Lung Cancer Therapeutics Product Specification
16.2.3 Sanofi Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Roche
16.3.1 Roche Company Profile
16.3.2 Roche Non-small Cell Lung Cancer Therapeutics Product Specification
16.3.3 Roche Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Novartis
16.4.1 Novartis Company Profile
16.4.2 Novartis Non-small Cell Lung Cancer Therapeutics Product Specification
16.4.3 Novartis Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Eli Lilly
16.5.1 Eli Lilly Company Profile
16.5.2 Eli Lilly Non-small Cell Lung Cancer Therapeutics Product Specification
16.5.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 AstraZeneca
16.6.1 AstraZeneca Company Profile
16.6.2 AstraZeneca Non-small Cell Lung Cancer Therapeutics Product Specification
16.6.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Pfizer
16.7.1 Pfizer Company Profile
16.7.2 Pfizer Non-small Cell Lung Cancer Therapeutics Product Specification
16.7.3 Pfizer Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Bristol-Myers Squibb
16.8.1 Bristol-Myers Squibb Company Profile
16.8.2 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Product Specification
16.8.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Non-small Cell Lung Cancer Therapeutics Manufacturing Cost Analysis
17.1 Non-small Cell Lung Cancer Therapeutics Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Non-small Cell Lung Cancer Therapeutics
17.4 Non-small Cell Lung Cancer Therapeutics Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Non-small Cell Lung Cancer Therapeutics Distributors List
18.3 Non-small Cell Lung Cancer Therapeutics Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Non-small Cell Lung Cancer Therapeutics (2021-2026)
20.2 Global Forecasted Revenue of Non-small Cell Lung Cancer Therapeutics (2021-2026)
20.3 Global Forecasted Price of Non-small Cell Lung Cancer Therapeutics (2015-2026)
20.4 Global Forecasted Production of Non-small Cell Lung Cancer Therapeutics by Region (2021-2026)
20.4.1 North America Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.3 Europe Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.7 Africa Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.9 South America Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Non-small Cell Lung Cancer Therapeutics Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.2 East Asia Market Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.3 Europe Market Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Countriy
21.4 South Asia Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.5 Southeast Asia Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.6 Middle East Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.7 Africa Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.8 Oceania Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.9 South America Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
21.10 Rest of the world Forecasted Consumption of Non-small Cell Lung Cancer Therapeutics by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer